Maze Therapeutics, Inc. (NASDAQ:MAZE – Get Free Report) CEO Jason Coloma sold 34,501 shares of the company’s stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $29.98, for a total value of $1,034,339.98. Following the transaction, the chief executive officer owned 23,337 shares of the company’s stock, valued at approximately $699,643.26. This represents a 59.65% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Maze Therapeutics Trading Up 4.9%
MAZE stock traded up $1.45 on Thursday, reaching $31.26. The company’s stock had a trading volume of 575,498 shares, compared to its average volume of 717,789. The firm has a market cap of $1.73 billion, a PE ratio of -12.36 and a beta of 2.14. The business has a fifty day simple moving average of $25.81 and a two-hundred day simple moving average of $35.73. Maze Therapeutics, Inc. has a 12-month low of $10.98 and a 12-month high of $53.65. The company has a debt-to-equity ratio of 0.11, a quick ratio of 17.88 and a current ratio of 17.88.
Maze Therapeutics (NASDAQ:MAZE – Get Free Report) last issued its quarterly earnings data on Tuesday, May 12th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.02). The business had revenue of $20.00 million for the quarter. As a group, research analysts forecast that Maze Therapeutics, Inc. will post -2.73 EPS for the current year.
Wall Street Analyst Weigh In
View Our Latest Stock Analysis on Maze Therapeutics
Institutional Investors Weigh In On Maze Therapeutics
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Royal Bank of Canada increased its stake in shares of Maze Therapeutics by 128.3% during the fourth quarter. Royal Bank of Canada now owns 646 shares of the company’s stock valued at $27,000 after purchasing an additional 363 shares in the last quarter. Ameritas Investment Partners Inc. boosted its position in shares of Maze Therapeutics by 82.6% in the 3rd quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock worth $42,000 after purchasing an additional 738 shares in the last quarter. California State Teachers Retirement System grew its stake in shares of Maze Therapeutics by 138.0% in the 4th quarter. California State Teachers Retirement System now owns 1,321 shares of the company’s stock worth $55,000 after buying an additional 766 shares during the last quarter. Police & Firemen s Retirement System of New Jersey grew its stake in shares of Maze Therapeutics by 18.5% in the 4th quarter. Police & Firemen s Retirement System of New Jersey now owns 5,961 shares of the company’s stock worth $247,000 after buying an additional 931 shares during the last quarter. Finally, GF Fund Management CO. LTD. bought a new position in Maze Therapeutics during the 4th quarter valued at approximately $39,000.
About Maze Therapeutics
Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.
Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.
Featured Articles
- Five stocks we like better than Maze Therapeutics
- Shorting the Grid: Bloom Energy’s $25B AI Power Play
- SanDisk’s Volatility May Be Telling Bulls What They Want to Hear
- Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive Weapon
- 3 Dividend ETFs Built for Stability in a Volatile Market
Receive News & Ratings for Maze Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maze Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
